Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7- year biochemical (PSA) progression analysis

Thomas J. Polascik, Charles R. Pound, Theodore DeWeese, Patrick Walsh

Research output: Contribution to journalArticle

Abstract

Objectives. To evaluate the relative efficacy of brachytherapy to radical prostatectomy, we compared biochemical progression rates from a published series of men who underwent iodine 125 (125I) interstitial radiotherapy for localized prostate cancer to a similar group of men who underwent anatomic radical prostatectomy using appropriate end points. Methods. Seventy-six men who underwent anatomic radical prostatectomy between 1988 and 1990 were carefully matched for Gleason score and clinical stage to a recently reported contemporary series of patients treated at another institution with 125I brachytherapy without adjuvant treatment. The definition of biochemical progression was a serum PSA level greater than 0.2 ng/mL after anatomic radical prostatectomy and greater than 0.5 ng/mL for brachytherapy-treated patients. Results. The 7-year actuarial PSA progression-free survival following anatomic radical prostatectomy was 97.8% (95% confidence interval [CI], 85.6% to 99.7%) for this group of men selected to match the brachytherapy group, compared to 79% (95% CI not published) for men treated with 125I interstitial radiotherapy. Conclusions. Using comparative end points for biochemical-free progression, failure rates may be higher following 125I interstitial radiotherapy compared to anatomic radical prostatectomy. These data provide a better comparison of biochemical progression than previously published studies and emphasize the need for caution in interpreting the relative efficacy of brachytherapy in controlling localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)884-890
Number of pages7
JournalUrology
Volume51
Issue number6
DOIs
StatePublished - Jun 1998

Fingerprint

Brachytherapy
Prostatectomy
Iodine
Prostatic Neoplasms
Therapeutics
Confidence Intervals
Neoplasm Grading
Disease-Free Survival
Serum

ASJC Scopus subject areas

  • Urology

Cite this

@article{b82d5e630fd049919c04d485dc6759e1,
title = "Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7- year biochemical (PSA) progression analysis",
abstract = "Objectives. To evaluate the relative efficacy of brachytherapy to radical prostatectomy, we compared biochemical progression rates from a published series of men who underwent iodine 125 (125I) interstitial radiotherapy for localized prostate cancer to a similar group of men who underwent anatomic radical prostatectomy using appropriate end points. Methods. Seventy-six men who underwent anatomic radical prostatectomy between 1988 and 1990 were carefully matched for Gleason score and clinical stage to a recently reported contemporary series of patients treated at another institution with 125I brachytherapy without adjuvant treatment. The definition of biochemical progression was a serum PSA level greater than 0.2 ng/mL after anatomic radical prostatectomy and greater than 0.5 ng/mL for brachytherapy-treated patients. Results. The 7-year actuarial PSA progression-free survival following anatomic radical prostatectomy was 97.8{\%} (95{\%} confidence interval [CI], 85.6{\%} to 99.7{\%}) for this group of men selected to match the brachytherapy group, compared to 79{\%} (95{\%} CI not published) for men treated with 125I interstitial radiotherapy. Conclusions. Using comparative end points for biochemical-free progression, failure rates may be higher following 125I interstitial radiotherapy compared to anatomic radical prostatectomy. These data provide a better comparison of biochemical progression than previously published studies and emphasize the need for caution in interpreting the relative efficacy of brachytherapy in controlling localized prostate cancer.",
author = "Polascik, {Thomas J.} and Pound, {Charles R.} and Theodore DeWeese and Patrick Walsh",
year = "1998",
month = "6",
doi = "10.1016/S0090-4295(98)00153-8",
language = "English (US)",
volume = "51",
pages = "884--890",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer

T2 - A 7- year biochemical (PSA) progression analysis

AU - Polascik, Thomas J.

AU - Pound, Charles R.

AU - DeWeese, Theodore

AU - Walsh, Patrick

PY - 1998/6

Y1 - 1998/6

N2 - Objectives. To evaluate the relative efficacy of brachytherapy to radical prostatectomy, we compared biochemical progression rates from a published series of men who underwent iodine 125 (125I) interstitial radiotherapy for localized prostate cancer to a similar group of men who underwent anatomic radical prostatectomy using appropriate end points. Methods. Seventy-six men who underwent anatomic radical prostatectomy between 1988 and 1990 were carefully matched for Gleason score and clinical stage to a recently reported contemporary series of patients treated at another institution with 125I brachytherapy without adjuvant treatment. The definition of biochemical progression was a serum PSA level greater than 0.2 ng/mL after anatomic radical prostatectomy and greater than 0.5 ng/mL for brachytherapy-treated patients. Results. The 7-year actuarial PSA progression-free survival following anatomic radical prostatectomy was 97.8% (95% confidence interval [CI], 85.6% to 99.7%) for this group of men selected to match the brachytherapy group, compared to 79% (95% CI not published) for men treated with 125I interstitial radiotherapy. Conclusions. Using comparative end points for biochemical-free progression, failure rates may be higher following 125I interstitial radiotherapy compared to anatomic radical prostatectomy. These data provide a better comparison of biochemical progression than previously published studies and emphasize the need for caution in interpreting the relative efficacy of brachytherapy in controlling localized prostate cancer.

AB - Objectives. To evaluate the relative efficacy of brachytherapy to radical prostatectomy, we compared biochemical progression rates from a published series of men who underwent iodine 125 (125I) interstitial radiotherapy for localized prostate cancer to a similar group of men who underwent anatomic radical prostatectomy using appropriate end points. Methods. Seventy-six men who underwent anatomic radical prostatectomy between 1988 and 1990 were carefully matched for Gleason score and clinical stage to a recently reported contemporary series of patients treated at another institution with 125I brachytherapy without adjuvant treatment. The definition of biochemical progression was a serum PSA level greater than 0.2 ng/mL after anatomic radical prostatectomy and greater than 0.5 ng/mL for brachytherapy-treated patients. Results. The 7-year actuarial PSA progression-free survival following anatomic radical prostatectomy was 97.8% (95% confidence interval [CI], 85.6% to 99.7%) for this group of men selected to match the brachytherapy group, compared to 79% (95% CI not published) for men treated with 125I interstitial radiotherapy. Conclusions. Using comparative end points for biochemical-free progression, failure rates may be higher following 125I interstitial radiotherapy compared to anatomic radical prostatectomy. These data provide a better comparison of biochemical progression than previously published studies and emphasize the need for caution in interpreting the relative efficacy of brachytherapy in controlling localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032101041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032101041&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(98)00153-8

DO - 10.1016/S0090-4295(98)00153-8

M3 - Article

C2 - 9609622

AN - SCOPUS:0032101041

VL - 51

SP - 884

EP - 890

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -